AR104510A1 - A STABLE TIOTROPE SOLUTION FOR NEBULIZERS - Google Patents

A STABLE TIOTROPE SOLUTION FOR NEBULIZERS

Info

Publication number
AR104510A1
AR104510A1 ARP160101255A ARP160101255A AR104510A1 AR 104510 A1 AR104510 A1 AR 104510A1 AR P160101255 A ARP160101255 A AR P160101255A AR P160101255 A ARP160101255 A AR P160101255A AR 104510 A1 AR104510 A1 AR 104510A1
Authority
AR
Argentina
Prior art keywords
tiotropium bromide
tiotropium
solution
tiotrope
nebulizers
Prior art date
Application number
ARP160101255A
Other languages
Spanish (es)
Inventor
Walley Jennifer
Edwards David
Hawkins Kevin
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of AR104510A1 publication Critical patent/AR104510A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación en solución para inhalación desde un nebulizador que consiste en tiotropio, agua, cloruro de sodio y un ácido seleccionado de HCl y ácido cítrico, o una mezcla de los mismos. Reivindicación 27: Un método para preparar la formulación de acuerdo con cualquiera de las reivindicaciones 1 - 15, en donde el tiotropio es bromuro de tiotropio y, antes de la disolución, el bromuro de tiotropio está en la forma de un solvato de bromuro de tiotropio, un hidrato de bromuro de tiotropio, bromuro de tiotropio anhidro o bromuro de tiotropio amorfo.Solution formulation for inhalation from a nebulizer consisting of tiotropium, water, sodium chloride and an acid selected from HCl and citric acid, or a mixture thereof. Claim 27: A method of preparing the formulation according to any of claims 1-15, wherein the tiotropium is tiotropium bromide and, prior to dissolution, tiotropium bromide is in the form of a tiotropium bromide solvate , a tiotropium bromide hydrate, anhydrous tiotropium bromide or amorphous tiotropium bromide.

ARP160101255A 2015-05-05 2016-05-03 A STABLE TIOTROPE SOLUTION FOR NEBULIZERS AR104510A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1507686.2A GB201507686D0 (en) 2015-05-05 2015-05-05 A stable tiotropium nebuliser solution

Publications (1)

Publication Number Publication Date
AR104510A1 true AR104510A1 (en) 2017-07-26

Family

ID=53489159

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101255A AR104510A1 (en) 2015-05-05 2016-05-03 A STABLE TIOTROPE SOLUTION FOR NEBULIZERS

Country Status (3)

Country Link
AR (1) AR104510A1 (en)
GB (1) GB201507686D0 (en)
WO (1) WO2016178019A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653683B2 (en) 2015-05-18 2020-05-19 Glenmark Specialty S.A. Tiotropium inhalation solution for nebulization
MX2017012272A (en) 2015-05-18 2018-06-19 Glenmark Specialty Sa Tiotropium inhalation solution for nebulization.
US9987260B2 (en) 2015-05-18 2018-06-05 Glenmark Specialty S.A. Tiotropium inhalation solution for nebulization
MX2019005563A (en) * 2016-11-16 2019-08-12 Glenmark Specialty Sa Nebulized tiotropium.
US20190231769A1 (en) * 2017-10-27 2019-08-01 Nephron Pharmaceuticals Corporation Tiotropium Inhalation Solution for Nebulization
US20200215051A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
EP4221707A4 (en) 2020-09-29 2024-08-28 Aerorx Therapeutics Llc Liquid formulations of indacaterol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
DE10216036A1 (en) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosol formulation for inhalation containing a tiotropium salt
US20040019073A1 (en) * 2002-04-11 2004-01-29 Boehringer Ingelheim Pharma Gmbh Co. Kg Aerosol formulation for inhalation containing a tiotropium salt
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
EP2044967A1 (en) * 2007-10-01 2009-04-08 Boehringer Ingelheim Pharma GmbH & Co. KG Atomiser

Also Published As

Publication number Publication date
GB201507686D0 (en) 2015-06-17
WO2016178019A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
AR104510A1 (en) A STABLE TIOTROPE SOLUTION FOR NEBULIZERS
NI201600018A (en) PYRROLAMIDE DERIVATIVES SUBSTITUTED WITH GLIOXAMIDE AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B.
CY1122712T1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
SV2017005555A (en) COMPOSITIONS OF OBETICOLIC ACID AND METHODS OF USE
NI201500161A (en) SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
AR096975A1 (en) AEROSOL LIQUID FORMULATION OF AN ELECTRONIC ITEM TO SMOKE
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
PE20151860A1 (en) DERIVATIVES OF 6- (5-HYDROXY-1H-PIRAZOL-1-IL) NICOTINAMIDE AND THEIR USE AS PHD INHIDERS
GT201300123A (en) DIMETHYL ACID SALT (ES) 7-CYCLOPENTIL-2- (5-PIPERAZIN-1-IL-PIRIDIN-2-IL-AMINO) -7H-PIRROLO- (2,3-D) -PIRIMIDIN-6- CARBOXILICO AND PROCESSES FOR ITS DEVELOPMENT
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
CO7131357A2 (en) N-aryltriazole compounds as lpar antagonists
AR087913A1 (en) REPLACED INHIBITORS OF N- [1-CIANO-2- (PHENYL) ETHYL] -2-AZABICICLO [2,2,1] HEPTAN-3-CARBOXAMIDE CATEPSIN
EA201692341A1 (en) SALT DAZATINIBA
UY35320A (en) ? HEXAHYDROPIRANE COMPOUNDS [3,4-d] [1,3] TIAZIN-2-AMINA REPLACED WITH HETEROARILE.
EA201591499A1 (en) SUBSTITUTED BISPHENYLBUTANE DERIVATIVES OF PHOSPHONE ACID AS NEP INHIBITORS (NEUTRAL ENDOPEPTIDASE)
CO7160077A2 (en) Pyrazole compounds substituted as lpar antagonists
MY178371A (en) Pharmaceutical preparation
CY1122596T1 (en) NEW PHARMACEUTICAL FORMS OF (TRIMETHOXYPHENYLAMINO)PYRIMIDINYL
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX2016014411A (en) Liquid formulation comprising gm-csf neutralizing compound.
AR089666A1 (en) STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION INCLUDING LEVOCETIRIZINE OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT, AND MONTELUKAST OR ONE OF ITS ACCEPTABLE SALTS FROM THE PHARMACEUTICAL VIEWPOINT
CY1122375T1 (en) TETRAHYDROFURAN-CONDENSED AMINOHYDROTHIAZINE ANALOGS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
UY32496A (en) DERIVATIVES OF N - [(6-AZA-BICYCLE [3.2.1] OCT-5-IL) -ARIL-METHYL) -HETEROBENZAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
CL2015001940A1 (en) Formulation comprising a benzothiazolone compound.

Legal Events

Date Code Title Description
FB Suspension of granting procedure